{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:27:52Z","timestamp":1758122872020},"reference-count":54,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Hyperinsulinemia is often associated with several metabolic abnormalities and increased blood pressure, which are risk factors for cardiovascular disease. It has been hypothesized that insulin resistance may underlie all these features. However, recent data suggest that some links between insulin resistance and these alterations may be indirect. The aim of our study was to further investigate this issue in a sample of young hyperandrogenic women, who often show insulin resistance and other metabolic abnormalities typical of the insulin resistance syndrome.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014We tested the hypothesis of a single factor underlying these features by principal component analysis, which should recognize one component if a single mechanism explains this association. The analysis was carried out in a sample of 255 young nondiabetic hyperandrogenic women. Variables selected for this analysis included the basic features of the insulin resistance syndrome and some endocrine parameters related to hyperandrogenism.<\/jats:p>\n               <jats:p>RESULTS\u2014Principal component analysis identified four separate factors, explaining 64.5% of the total variance in the data: the first included fasting and postchallenge insulin levels, BMI, triglycerides, HDL cholesterol, and uric acid; the second, BMI, blood pressure, and serum free testosterone; the third, fasting plasma glucose, postchallenge glucose and insulin levels, serum triglycerides, and free testosterone; and the fourth, postchallenge plasma insulin, serum free testosterone, and gonadotropin-releasing hormone agonist\u2013stimulated 17-hydroxyprogesterone.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014These results support the hypothesis of multiple determinants in the clustering of abnormalities in the so-called insulin resistance syndrome.<\/jats:p>","DOI":"10.2337\/diacare.29.02.06.dc05-1478","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T22:41:57Z","timestamp":1147300917000},"page":"372-378","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":18,"title":["Clustering of Cardiovascular Risk Factors Associated With the Insulin Resistance Syndrome"],"prefix":"10.2337","volume":"29","author":[{"given":"M. Elisabetta","family":"Zanolin","sequence":"first","affiliation":[{"name":"Unit of Epidemiology and Medical Statistics, Department of Public Medicine and Health, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Tosi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Zoppini","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Castello","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Spiazzi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romolo","family":"Dorizzi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Muggeo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Moghetti","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031218004212500_R1","doi-asserted-by":"crossref","unstructured":"Reaven GM: Role of insulin resistance in human diseases. Diabetes\u200837: 1595\u2013607, 1988","DOI":"10.2337\/diab.37.12.1595"},{"key":"2022031218004212500_R2","doi-asserted-by":"crossref","unstructured":"DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care\u200814:173\u2013194, 1991","DOI":"10.2337\/diacare.14.3.173"},{"key":"2022031218004212500_R3","doi-asserted-by":"crossref","unstructured":"Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes\u200841:715\u2013722, 1992","DOI":"10.2337\/diabetes.41.6.715"},{"key":"2022031218004212500_R4","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA\u2008285:2486\u20132497, 2001","DOI":"10.1001\/jama.285.19.2486"},{"key":"2022031218004212500_R5","doi-asserted-by":"crossref","unstructured":"Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: finding from the Third National Health and Nutrition Examination Survey. JAMA\u2008287:356\u2013359, 2002","DOI":"10.1001\/jama.287.3.356"},{"key":"2022031218004212500_R6","doi-asserted-by":"crossref","unstructured":"Meigs JB, D\u2019Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome. Diabetes\u200846:1594\u20131600, 1997","DOI":"10.2337\/diacare.46.10.1594"},{"key":"2022031218004212500_R7","doi-asserted-by":"crossref","unstructured":"Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev\u200818:774\u2013800, 1997","DOI":"10.1210\/er.18.6.774"},{"key":"2022031218004212500_R8","doi-asserted-by":"crossref","unstructured":"Lobo RA, Carmina E: The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med\u2008132:989\u2013993, 2000","DOI":"10.7326\/0003-4819-132-12-200006200-00010"},{"key":"2022031218004212500_R9","doi-asserted-by":"crossref","unstructured":"Wild RA: Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol\u2008186:35\u201343, 2002","DOI":"10.1067\/mob.2002.119180"},{"key":"2022031218004212500_R10","doi-asserted-by":"crossref","unstructured":"Ovalle F, Azziz R: Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril\u200877:1095\u20131105, 2002","DOI":"10.1016\/S0015-0282(02)03111-4"},{"key":"2022031218004212500_R11","doi-asserted-by":"crossref","unstructured":"Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC: The insulin-related ovarian regulatory system in health and disease. Endocr Rev\u200820:535\u2013582, 1999","DOI":"10.1210\/edrv.20.4.0374"},{"key":"2022031218004212500_R12","doi-asserted-by":"crossref","unstructured":"Nestler JE: Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes\u20087:345\u2013349, 2000","DOI":"10.1097\/00060793-200012000-00009"},{"key":"2022031218004212500_R13","doi-asserted-by":"crossref","unstructured":"Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract\u20089:237\u2013252, 2003","DOI":"10.4158\/EP.9.S2.5"},{"key":"2022031218004212500_R14","doi-asserted-by":"crossref","unstructured":"Hatch R, Rosenfield RL, Kim MH, Tredway D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol\u2008140:815\u2013830, 1981","DOI":"10.1016\/0002-9378(81)90746-8"},{"key":"2022031218004212500_R15","doi-asserted-by":"crossref","unstructured":"Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA: Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med\u2008320:559\u2013565, 1989","DOI":"10.1056\/NEJM198903023200904"},{"key":"2022031218004212500_R16","doi-asserted-by":"crossref","unstructured":"Rosenfield RL, Ehrmann DA, Barnes RB, Sheikh Z: Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci\u2008687:162\u2013181, 1993","DOI":"10.1111\/j.1749-6632.1993.tb43864.x"},{"key":"2022031218004212500_R17","doi-asserted-by":"crossref","unstructured":"Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev\u200816:322\u2013369, 1995","DOI":"10.1210\/er.16.3.322"},{"key":"2022031218004212500_R18","doi-asserted-by":"crossref","unstructured":"Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab\u200881:952\u2013960, 1996","DOI":"10.1210\/jcem.81.3.8772557"},{"key":"2022031218004212500_R19","doi-asserted-by":"crossref","unstructured":"Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M: Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab\u200880:836\u2013840, 1995","DOI":"10.1210\/jcem.80.3.7883839"},{"key":"2022031218004212500_R20","doi-asserted-by":"crossref","unstructured":"Moghetti P, Castello R: New routes in the polycystic ovary syndrome labyrinth: a way out? J Endocrinol Invest\u200821:648\u2013655, 1998","DOI":"10.1007\/BF03350793"},{"key":"2022031218004212500_R21","doi-asserted-by":"crossref","unstructured":"Wild RA: Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med\u200898 (Suppl. 1A):27S\u201332S, 1995","DOI":"10.1016\/S0002-9343(99)80056-4"},{"key":"2022031218004212500_R22","doi-asserted-by":"crossref","unstructured":"Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S: Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol\u200844:277\u2013284, 1996","DOI":"10.1046\/j.1365-2265.1996.674495.x"},{"key":"2022031218004212500_R23","doi-asserted-by":"crossref","unstructured":"Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev\u200824:302\u2013312, 2003","DOI":"10.1210\/er.2003-0004"},{"key":"2022031218004212500_R24","doi-asserted-by":"crossref","unstructured":"Holte J, Gennarelli G, Berne C, Bergh T, Lithell H: Elevated ambulatory day-time pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod\u200811:23\u201328, 1996","DOI":"10.1093\/oxfordjournals.humrep.a019028"},{"key":"2022031218004212500_R25","doi-asserted-by":"crossref","unstructured":"Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril\u200857:505\u2013513, 1992","DOI":"10.1016\/S0015-0282(16)54892-4"},{"key":"2022031218004212500_R26","doi-asserted-by":"crossref","unstructured":"Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol\u200815:821\u2013826, 1995","DOI":"10.1161\/01.ATV.15.7.821"},{"key":"2022031218004212500_R27","doi-asserted-by":"crossref","unstructured":"Conway GS, Agrawal R, Betteridge DJ, Jacobs HS: Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol\u200837:119\u2013125, 1992","DOI":"10.1111\/j.1365-2265.1992.tb02295.x"},{"key":"2022031218004212500_R28","doi-asserted-by":"crossref","unstructured":"Wild RA, Alaupovic P, Parker IJ: Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol\u2008166:1191\u20131197, 1992","DOI":"10.1016\/S0002-9378(11)90605-X"},{"key":"2022031218004212500_R29","doi-asserted-by":"crossref","unstructured":"Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism\u200852:908\u2013915, 2003","DOI":"10.1016\/S0026-0495(03)00104-5"},{"key":"2022031218004212500_R30","doi-asserted-by":"crossref","unstructured":"Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab\u200890:1929\u20131935, 2005","DOI":"10.1210\/jc.2004-1045"},{"key":"2022031218004212500_R31","doi-asserted-by":"crossref","unstructured":"Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes\u200847:1643\u20131649, 1998","DOI":"10.2337\/diabetes.47.10.1643"},{"key":"2022031218004212500_R32","doi-asserted-by":"crossref","unstructured":"Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med\u2008317:350\u2013357, 1987","DOI":"10.1056\/NEJM198708063170605"},{"key":"2022031218004212500_R33","doi-asserted-by":"crossref","unstructured":"Zavaroni I, Bonora E, Pagliara M, Dall\u2019Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Passeri M, Reaven G: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med\u2008320:502\u2013506, 1989","DOI":"10.1056\/NEJM198903163201105"},{"key":"2022031218004212500_R34","doi-asserted-by":"crossref","unstructured":"Falkner B, Hulman D, Tannebaum J, Kushner H: Insulin resistance and blood pressure in young black men. Hypertension\u200816:706\u2013711, 1990","DOI":"10.1161\/01.HYP.16.6.706"},{"key":"2022031218004212500_R35","doi-asserted-by":"crossref","unstructured":"Mbanya JCN, Thomas TH, Wilkinson R, Alberti KGMM, Taylor R: Hypertension and hyperinsulinemia: a relation in diabetics but not in essential hypertension. Lancet\u20081:733\u2013734, 1988","DOI":"10.1016\/S0140-6736(88)91538-3"},{"key":"2022031218004212500_R36","doi-asserted-by":"crossref","unstructured":"Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, DeGregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV, Bogardus C: Racial differences in the relationship with blood pressure and insulin resistance. N Engl J Med\u2008324:733\u2013739, 1991","DOI":"10.1056\/NEJM199103143241105"},{"key":"2022031218004212500_R37","doi-asserted-by":"crossref","unstructured":"Muller DC, Elahi D, Pratley RE, Tobin JD, Andres R: An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab\u200876:544\u2013548, 1993","DOI":"10.1210\/jcem.76.3.8445009"},{"key":"2022031218004212500_R38","doi-asserted-by":"crossref","unstructured":"Haffner SM, Ferrannini E, Hazuda HP, Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension\u200820:38\u201345, 1992","DOI":"10.1161\/01.HYP.20.1.38"},{"key":"2022031218004212500_R39","doi-asserted-by":"crossref","unstructured":"Franks S, Kiddy D, Sharp P, Singh A, Reed M, Seppala M, Koistinen R, Hamilton-Fairley D: Obesity and polycystic ovary syndrome. Ann N Y Acad Sci\u2008626:201\u2013206, 1991","DOI":"10.1111\/j.1749-6632.1991.tb37915.x"},{"key":"2022031218004212500_R40","doi-asserted-by":"crossref","unstructured":"Pasquali R, Casimirri F: The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf)\u200839:1\u201316, 1993","DOI":"10.1111\/j.1365-2265.1993.tb01744.x"},{"key":"2022031218004212500_R41","doi-asserted-by":"crossref","unstructured":"Holte J: Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? J Endocrinol Invest\u200821:589\u2013601, 1998","DOI":"10.1007\/BF03350784"},{"key":"2022031218004212500_R42","doi-asserted-by":"crossref","unstructured":"Brown WV: Lipoprotein disorders in diabetes mellitus. Med Clin North Am\u200878:143\u2013161, 1994","DOI":"10.1016\/S0025-7125(16)30180-8"},{"key":"2022031218004212500_R43","doi-asserted-by":"crossref","unstructured":"Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R, Krakoff LR: Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab\u200875:508\u2013513, 1992","DOI":"10.1210\/jcem.75.2.1639952"},{"key":"2022031218004212500_R44","doi-asserted-by":"crossref","unstructured":"Sampson M, Kong C, Patel A, Unwin R, Jacobs HS: Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol\u200845:623\u2013629, 1996","DOI":"10.1046\/j.1365-2265.1996.00863.x"},{"key":"2022031218004212500_R45","doi-asserted-by":"crossref","unstructured":"DeFronzo RA: The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes\u200837:667\u2013687, 1988","DOI":"10.2337\/diab.37.6.667"},{"key":"2022031218004212500_R46","doi-asserted-by":"crossref","unstructured":"Barbieri RL, Makris A, Randall RW, Daniels G, Kristner RW, Ryan KJ: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab\u200862:904\u2013910, 1986","DOI":"10.1210\/jcem-62-5-904"},{"key":"2022031218004212500_R47","doi-asserted-by":"crossref","unstructured":"Nestler JE, Jakubowicz DJ, De Vargas AF, Brik C, Quintero N, Medina F: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab\u200883:2001\u20132005, 1998","DOI":"10.1210\/jc.83.6.2001"},{"key":"2022031218004212500_R48","doi-asserted-by":"crossref","unstructured":"Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M: Insulin infusion amplifies 17\u03b1-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab\u200881:881\u2013886, 1996","DOI":"10.1210\/jcem.81.3.8772544"},{"key":"2022031218004212500_R49","doi-asserted-by":"crossref","unstructured":"Nestler JE, Powers LP, Matt DW: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab\u200872:83\u201389, 1991","DOI":"10.1210\/jcem-72-1-83"},{"key":"2022031218004212500_R50","doi-asserted-by":"crossref","unstructured":"Plymate SR, Matej LA, Jones RE: Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab\u200867:460\u2013464, 1988","DOI":"10.1210\/jcem-67-3-460"},{"key":"2022031218004212500_R51","doi-asserted-by":"crossref","unstructured":"Holmang A, Svedberg J, Jennische E, Bjorntorp P: Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol\u2008259:E555\u2013E560, 1990","DOI":"10.1152\/ajpendo.1990.259.4.E555"},{"key":"2022031218004212500_R52","doi-asserted-by":"crossref","unstructured":"Speiser PW, Serrat J, New MI, Gertner JM: Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab\u200875:1421\u20131424, 1992","DOI":"10.1210\/jcem.75.6.1464643"},{"key":"2022031218004212500_R53","doi-asserted-by":"crossref","unstructured":"Diamond MP, Grainger D, Diamond MC, Sherwin RS, DeFronzo RA: Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab\u200883:4420\u20134425, 1998","DOI":"10.1210\/jc.83.12.4420"},{"key":"2022031218004212500_R54","doi-asserted-by":"crossref","unstructured":"Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A: Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women. Am J Epidemiol\u2008160:540\u2013548, 2004","DOI":"10.1093\/aje\/kwh250"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/29\/2\/372\/594086\/zdc00206000372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/29\/2\/372\/594086\/zdc00206000372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T18:56:32Z","timestamp":1647111392000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/29\/2\/372\/26289\/Clustering-of-Cardiovascular-Risk-Factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.29.02.06.dc05-1478","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}